Key result
Argatroban successfully maintains anticoagulation during CPB for mitral valve replacement in a heparin-allergic patient.
Why the study?
Can argatroban be safely and effectively used for anticoagulation during cardiopulmonary bypass in a patient with heparin allergy?
Case Report (n=1)
Can argatroban be safely and effectively used for anticoagulation during cardiopulmonary bypass in a patient with heparin allergy?
Argatroban may serve as a viable off-label alternative for anticoagulation during cardiopulmonary bypass in patients with heparin allergy.
May offer an off-label alternative for CPB anticoagulation in heparin allergy; leaves open need for prospective safety data.
The use of Argatroban for treatment of heparin-induced thrombocytopenia (HIT) and for percutaneous coronary intervention in patients with HIT is well described and FDA approved. The use of Argatroban for cardiopulmonary bypass remains off label and the subject of a few case reports. We report the case of a patient with a heparin allergy requiring cardiopulmonary bypass (CPB) for mitral valve replacement. Argatroban was successfully used as anticoagulation for CPB.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2008) conducted a case report in Heparin allergy requiring cardiopulmonary bypass (n=1). Argatroban was evaluated on Successful anticoagulation for CPB. Argatroban was successfully used as anticoagulation during cardiopulmonary bypass for mitral valve replacement in a patient with a heparin allergy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: